Kathy Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) and her collaborators has identified a mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse. Kathy Borden is a Principal Investigator at IRIC and a professor at the university's Department of Pathology and Cell Biology. The development of drug resistance is one of the main problems in clinical ...
Read More
No comments:
Post a Comment